3,4-dimethylthiophene-2-carbaldehyde | 343268-79-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3,4-dimethylthiophene-2-carbaldehyde
• 英文别名: 3,4-Dimethyl-thiophen-2-carbaldehyd
• CAS: 343268-79-1
• 化学式: C₇H₈OS
• 分子量: 140.206
• InChiKey: BKJFHBZANQQLNO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,4-dimethylthiophene-2-carbaldehyde 在 氢氧化钾 、 水 作用下， 生成 2,3,5-三甲基噻吩
  参考文献：
  名称：

  Acylation Studies in the Thiophene and Furan Series.^1a VIII. Mixed Melting Points of Some Homologous Acetylmethylthiophene Derivatives

  摘要：

  DOI：

  10.1021/ja01152a525
• 作为产物：
  描述：

  3,4-二甲基噻吩 、 N-甲基甲酰苯胺 在 三氯氧磷 作用下， 生成 3,4-dimethylthiophene-2-carbaldehyde
  参考文献：
  名称：

  STUDIES ON THE CHEMISTRY OF HETEROCYCLICS. XI. FURTHER REACTIONS OF THENALDEHYDES.¹

  摘要：

  DOI：

  10.1021/jo01152a009

文献信息

• Method of producing an o-disubstituted aromatic compound, and method of producing a monosubstituted-monohaloaromatic compound
  申请人：Yoshida Jun-ichi

  公开号：US20080194816A1

  公开（公告）日：2008-08-14

  A method of producing an o-disubstituted aromatic compound, containing: continuously conducting at least the following steps (a) to (d): (a) a step of mono-lithiating one halogen atom of an o-dihaloaromatic compound, using a first microreactor; (b) a step of making the thus-obtained monolithiated product to react with an electrophilic compound, using a second microreactor, to obtain a monosubstituted-monohaloaromatic compound; (c) a step of lithiating the other halogen atom of the o-dihaloaromatic compound, using a third microreactor; and (d) a step of making the thus-obtained lithiated product successively to react with an electrophilic compound, using a forth microreactor.

  生产 o-二取代芳香化合物的方法，包括：连续进行至少以下步骤（a）至（d）： (a) 使用第一微反应器对 o-二卤代芳香化合物的一个卤原子进行单锂化步骤； (b) 使用第二微反应器使得所得的单锂化产物与亲电性化合物发生反应，以获得单取代-单卤代芳香化合物的步骤； (c) 使用第三微反应器对 o-二卤代芳香化合物的另一个卤原子进行锂化步骤；以及 (d) 使用第四微反应器使得所得的锂化产物依次与亲电性化合物发生反应的步骤。
• [EN] 3-(PYRIDIN-3-YL)-ACRYLAMIDE AND N-(PYRIDIN-3-YL)-ACRYLAMIDE DERIVATIVES AND THEIR USE AS PAK OR NAMPT MODULATORS<br/>[FR] DÉRIVÉS 3-(PYRIDIN-3-YL)-ACRYLAMIDE ET N-(PYRIDIN-3-YL)-ACRYLAMIDE ET LEUR UTILISATION COMME MODULATEURS DE PAK OU NAMPT
  申请人：KARYOPHARM THERAPEUTICS INC

  公开号：WO2017031213A1

  公开（公告）日：2017-02-23

  The invention generally relates to cyclic compounds and, more particularly, to a compound represented by Structural Formula I: or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the multicyclic compounds. The invention also relates to a method for treating a disease or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a T- Cell mediated autoimmune diseases) in a subject in need thereof. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof.

  该发明通常涉及环状化合物，更具体地涉及由结构式I表示的化合物：或其药学上可接受的盐以及包含多环化合物的药物组合物。该发明还涉及一种治疗癌症（例如淋巴瘤，如边缘区淋巴瘤）、神经退行性疾病、炎症性疾病或免疫系统疾病（例如T细胞介导的自身免疫疾病）的方法，该方法包括向需要的受试者施用该发明的化合物或其药学上可接受的盐的治疗有效量，或者包括该发明的化合物或其药学上可接受的盐的组合物。
• TRIARYLMETHANE COMPOUNDS AS REDOX INDICATORS IN THE SCHOENEMANN REACTION: II. SYNTHESES OF THE TRIARYLMETHANES
  作者：D. Morison Smith、R. Blanchfield、J. L. Thompson、G. A. Grant

  DOI：10.1139/v57-023

  日期：1957.2.1

  The syntheses and properties of a series of 4,4′-thenylidene bis[N,N-dimethylaniline] compounds, variously substituted in the thiophene ring, are reported. These compounds were tested as redox indicators in the Schoenemann reaction for the detection of phosphonofluoridate esters in solution. The most effective indicator was 4,4′(5-methyl-4-propyl-2-thenylidene)bis[N,N-dimethylaniline]

  报道了一系列在噻吩环中不同取代的4,4'-亚乙基双[N,N-二甲基苯胺]化合物的合成和性质。这些化合物被用作Schönenmann反应中检测溶液中磷酸氟酯酯的氧化还原指示剂。其中最有效的指示剂是4,4'(5-甲基-4-丙基-2-亚乙基)双[N,N-二甲基苯胺]。
• Porphyrin compositions
  申请人：Litz Erik Kyle

  公开号：US20060152149A1

  公开（公告）日：2006-07-13

  Novel metal porphyrin compositions useful as organic phosphors are provided. The novel compositions are prepared from commercially available porphyrin-containing starting materials. In one instance a novel palladium-containing porphyrin composition having a number average molecular weight of greater than 12,000 grams per mole was prepared from 5,10,15,20-tetrakis(3′,5′-di(hydroxy)phenyl)-21H-23H-porphyrin by reaction first with palladium(II) acetylacetonate, followed by reaction with 2-bromo-2-methylpropionyl bromide, and subsequent group transfer reaction of the alpha-bromo ester groups with 9,9-dioctyl-2-vinylfluorene in the presence of CuBr as a radical initiator. The product polymer exhibited a number average molecular weight of 12,884 grams per mole, a weight average molecular weight of 14,338 grams per mole, and a robust red phosphorescent emission. Porphyrin containing copoylmers comprising structural units derived from 9,9-dioctyl-2-vinylfluorene and 9-anthracenylmethyl methacrylate were prepared in a similar fashion.

  提供用作有机荧光体的新型金属卟啉组合物。这些新型组合物是从商业可获得的含卟啉起始原料制备的。在一个实例中，通过首先与醋酸钯(II)反应，然后与2-溴-2-甲基丙酰溴反应，并在CuBr存在下将α-溴酯基团与9,9-二辛基-2-乙烯基芴进行基团转移反应，制备了一个平均分子量大于12,000克/摩尔的新型含钯卟啉组合物，起始原料为5,10,15,20-四(3′,5′-二(羟基)苯基)-21H-23H-卟啉。该产物聚合物的平均分子量为12,884克/摩尔，重均分子量为14,338克/摩尔，具有稳健的红色磷光发射。类似地制备了含卟啉的共聚物，其结构单元源自9,9-二辛基-2-乙烯基芴和9-蒽甲基丙烯酸甲酯。
• [EN] NECROSIS INHIBITORS<br/>[FR] INHIBITEURS DE NÉCROSE
  申请人：NAT INST OF BIOLOG SCIENCES BEIJING

  公开号：WO2016101885A1

  公开（公告）日：2016-06-30

  The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

  该发明提供了抑制细胞坏死和/或人类受体相互作用蛋白1激酶（RIP1）的酰胺，包括相应的磺酰胺以及其药用可接受的盐、氢化物和立体异构体。这些化合物用于制备药物组合物，并用于制备和使用方法，包括以有效量的该化合物或组合物治疗需要的人，并检测该人的健康或状况的改善。